Article

Proteomic Approaches to the Discovery of Cancer Biomarkers for Early Detection and Personalized Medicine.

Department of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan.
Japanese Journal of Clinical Oncology (Impact Factor: 1.9). 12/2012; DOI:10.1093/jjco/hys200
Source: PubMed

ABSTRACT Cancer biomarkers for the early detection of malignancies and selection of therapeutic strategies have been requested in the clinical field. Accurate and informative cancer biomarkers hold significant promise for improvements in the early detection of disease and in the selection of the most effective therapeutic strategies. Recently, significant progress in the comprehensive analysis of the human genome, epigenome, transcriptome, proteome and metabolome has led to revolutionary changes in the discovery of cancer biomarkers. The Human Proteome Organization has launched a global Human Proteome Project to map the entire human protein set. The Human Proteome Project research group has focused on three working proteomic pillars-mass spectrometry-based, antibody-based and knowledge-based proteomics-and each of these technologies is advancing rapidly. In this review, we introduce the proteomic platforms that are currently being used for cancer biomarker discovery, and describe examples of novel cancer biomarkers that were identified with each proteomic technology.

0 0
 · 
1 Bookmark
 · 
1,502 Views
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: The advancement of modern therapy concepts has dramatically extended the postsurvival rates of patients with malignant gastric cancer. However, a remaining setback is the drug resistance of recurrent cancer, which casts a dark shadow over disease prognosis. The original work of Klein et al. [Proteomics Clin. Appl. 2013, 7, 813-824] has outlined a rational experimental approach to decipher the mechanistic pathway of cancer drug resistance by proteomic approach. They used gel-based comparative proteomics to analyze the nuclear proteome of a human gastric cancer cell line (AGS) with and without inactivation of hypoxia-inducible factor 1 (HIF-1), a transcription factor and master regulator of hypoxia adaptation. Using the classical 2DE-MS approach, these researchers observed 163 HIF-1 responsive proteins, among which over half of them could be confidently identified by MS. From this large dataset, the authors proposed an enhanced nuclear translocation of some proteasomal proteins upon inactivation of HIF-1. Overall, this work appropriately used proteomics as a hypothesis-free, top-down approach to dissect imperative clinical problems.
    PROTEOMICS - CLINICAL APPLICATIONS 12/2013; 7(11-12):723-4. · 1.81 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Despite remarkable progress in proteomic methods, including improved detection limits and sensitivity, these methods have not yet been established in routine clinical practice. The main limitations, which prevent their integration into clinics, are high cost of equipment, the need for highly trained personnel, and last, but not least, the establishment of reliable and accurate protein biomarkers or panels of protein biomarkers for detection of neoplasms. Furthermore, the complexity and heterogeneity of most solid tumours present obstacles in the discovery of specific protein signatures, which could be used for early detection of cancers, for prediction of disease outcome, and for determining the response to specific therapies. However, cancer proteome, as the end-point of pathological processes that underlie cancer development and progression, could represent an important source for the discovery of new biomarkers and molecular targets for tailored therapies.
    The Scientific World Journal 01/2014; 2014:260348. · 1.73 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: A high sensitivity assay has been developed for the detection of human Topoisomerase I with single molecule resolution. The method uses magnetic sepharose beads to concentrate rolling circle products, produced by the amplification of DNA molecules circularized by Topoisomerase I and detectable at a confocal microscope as single and discrete dots, once reacted with fluorescent probes. Each dot, corresponding to a single cleavage-religation event mediated by the enzyme, can be counted due to its high signal/noise ratio allowing detection of 0.3 pM of enzyme and representing a valid method to detect the enzyme activity in highly diluted samples.
    Analytical Biochemistry 02/2014; · 2.58 Impact Factor

Full-text

View
298 Downloads
Available from
Dec 21, 2012